Abstract: Provided herein are composition and methods for the treatment of cancer by the administration of uropathogenic bacteria. In particular, CP1 E. coli is administered for the treatment of prostate cancer.

Abstract: Provided herein are composition and methods for the treatment of cancer by the administration of uropathogenic bacteria. In particular, CP1 E. coli is administered for the treatment of prostate cancer.

Abstract: Provided herein are compositions and methods for the treatment of conditions such as benign prostatic hyperplasia (BPH), Lower Urinary Tract Symptoms (LUTS), chronic prostatitis (CP) and/or chronic pelvic pain syndrome (CPPS). In particular, provided herein are combination therapies comprising a mast cell inhibitor and a histamine receptor antagonist.

Abstract: Disclosed herein are systems and methods for significantly improving the accuracy of drug selection for patients diagnosed with, or symptomatic for, urinary tract infections (UTIs). In some embodiments, the systems and methods utilize real-time patient data linked to geographic distribution maps of resistance to different antimicrobial treatments for UTIs. The combination of real-time date and resistance maps allow for more accurate selection of appropriate UTI therapy for the patient.

Abstract: Provided are methods for treating acute and recurring urinary tract infections in dogs.

Abstract: Provided herein are compositions and methods for the treatment of conditions such as benign prostatic hyperplasia (BPH), Lower Urinary Tract Symptoms (LUTS), chronic prostatitis (CP) and/or chronic pelvic pain syndrome (CPPS). In particular, provided herein are combination therapies comprising a mast cell inhibitor and a histamine receptor antagonist.

Abstract: Provided are methods for treating acute and recurring urinary tract infections in dogs.

Abstract: Provided herein are kits, compositions, and methods for diagnosing and treating interstitial cystitis (IC) and/or interstitial cystitis/bladder pain syndrome (IC/BPS) based on finding lower levels of certain bacteria in a subject's stool sample (e.g., O. splanchnicus, F. prausnitzii, C. aerofaciens, E. sinensis, L. longoviformis, and R. intestinalis). In certain embodiments, then present invention provides probiotic formulations containing live bacteria (e.g., from O. splanchnicus, F. prausnitzii, C. aerofaciens, E. sinensis, L. longoviformis, and R. intestinalis).

Abstract: Provided herein are kits, compositions, and methods for diagnosing and treating interstitial cystitis (IC) and/or interstitial cystitis/bladder pain syndrome (IC/BPS) based on finding lower levels of certain bacteria in a subject's stool sample (e.g., O. splanchnicus, F. prausnitzii, C. aerofaciens, E. sinensis, L. longoviformis, and R. intestinalis). In certain embodiments, then present invention provides probiotic formulations containing live bacteria (e.g., from O. splanchnicus, F. prausnitzii, C. aerofaciens, E. sinensis, L. longoviformis, and R. intestinalis).

Abstract: Provided herein are composition and methods for the treatment of cancer by the administration of uropathogenic bacteria. In particular, CP1 E. coli is administered for the treatment of prostate cancer.

Abstract: The present invention provides compositions and methods for treatment or prevention of pain resulting from infection, infection related pain, and non-infectious pain as well as treatment or prevention of infections or adverse health consequences associated with infections.

Abstract: The present invention provides compositions and methods for treatment or prevention of pain resulting from infection, infection related pain, and non-infectious pain as well as treatment or prevention of infections or adverse health consequences associated with infections.

Abstract: Provided herein are kits, compositions, and methods for diagnosing and treating interstitial cystitis (IC) and/or interstitial cystitis/bladder pain syndrome (IC/BPS) based on finding lower levels of certain bacteria in a subject's stool sample (e.g., O. splanchnicus, F. prausnitzii, C. aerofaciens, E. sinensis, L. longoviformis, and R. intestinalis). In certain embodiments, then present invention provides probiotic formulations containing live bacteria (e.g., from O. splanchnicus, F. prausnitzii, C. aerofaciens, E. sinensis, L. longoviformis, and R. intestinalis).

Abstract: Provided herein are kits, compositions, and methods for diagnosing and treating interstitial cystitis (IC) and/or interstitial cystitis/bladder pain syndrome (IC/BPS) based on finding lower levels of certain bacteria in a subject's stool sample (e.g., O. splanchnicus, F. prausnitzii, C. aerofaciens, E. sinensis, L. longoviformis, and R. intestinalis). In certain embodiments, then present invention provides probiotic formulations containing live bacteria (e.g., from O. splanchnicus, F. prausnitzii, C. aerofaciens, E. sinensis, L. longoviformis, and R. intestinalis).

Abstract: The present invention provides compositions and methods for detection, diagnosis, treatment and/or prevention of chronic pelvic pain syndrome. In particular, the present invention provides biomarkers of chronic pelvic pain syndrome (e.g., mast cell markers (e.g., tryptase)), and/or inhibition of mast cell function (e g inhibition of MCP-1 and/or MIP-1?) to treat or prevent chronic pelvic pain syndrome.

Abstract: The present invention provides compositions and methods for treatment or prevention of pain resulting from infection, infection related pain, and non-infectious pain as well as treatment or prevention of infections or adverse health consequences associated with infections.

Abstract: The present invention provides compositions and methods for detection, diagnosis, treatment and/or prevention of chronic pelvic pain syndrome. In particular, the present invention provides biomarkers of chronic pelvic pain syndrome (e.g., mast cell markers (e.g., tryptase)), and/or inhibition of mast cell function (e.g. inhibition of MCP-1 and/or MIP-1?) to treat or prevent chronic pelvic pain syndrome.

Abstract: Provided herein are kits, compositions, and methods for diagnosing and treating interstitial cystitis (IC) and/or interstitial cystitis/bladder pain syndrome (IC/BPS) based on finding lower levels of certain bacteria in a subject's stool sample (e.g., O. splanchnicus, F. prausnitzii, C. aerofaciens, E. sinensis, L. longoviformis, and R. intestinalis). In certain embodiments, then present invention provides probiotic formulations containing live bacteria (e.g., from O. splanchnicus, F. prausnitzii, C. aerofaciens, E. sinensis, L. longoviformis, and R. intestinalis).

Abstract: The present invention provides methods and compositions for treating chronic pelvic pain syndrome. In particular, the present invention provides methods and compositions for treating chronic pelvic pain syndrome with an agent that targets MCP-1, MIP-1?, or the CCR-2 receptor.

Abstract: The present invention provides compositions and methods for detection, diagnosis, treatment and/or prevention of chronic pelvic pain syndrome. In particular, the present invention provides biomarkers of chronic pelvic pain syndrome (e.g., mast cell markers (e.g., tryptase)), and/or inhibition of mast cell function (e.g. inhibition of MCP-1 and/or MIP-1?) to treat or prevent chronic pelvic pain syndrome.